olomoucine has been researched along with Carcinoma, Anaplastic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| David-Pfeuty, T | 1 |
1 other study(ies) available for olomoucine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Line; Cell Line, Transformed; Cell Nucleolus; Cell Nucleus; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; G1 Phase; Humans; Inhibitory Concentration 50; Kinetin; Mitomycin; Nucleic Acid Synthesis Inhibitors; Nucleolin; Phosphoproteins; Protein Serine-Threonine Kinases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |